Table 3.

Estimated and reported milestone survival probabilities using the treatment effect calculator (Supplementary File S1) assuming an exponential survival distribution in adjuvant therapy trials. DFS = disease-free survival, HR = hazard ratio.

Type of Adjuvant Therapy	Milestone Time (Months)	Reported Milestone DFS Probability in Control Group	Estimated HR and CIs for DFS	Estimated Milestone DFS Probability in Treatment Group	Reported Milestone DFS Probability in Treatment Group	Difference between Estimated Versus Reported Milestone DFS Probability	Reference
Immune checkpoint therapy vs. placebo	12	76.2%	0.68	83.1%	85.7%	−2.6%	[9]
Immune checkpoint therapy vs. placebo	24	68.1%	0.68	77%	77.3%	−0.3%	[9]
Immune checkpoint therapy vs. placebo	6	60.3%	0.70	70.2%	74.9%	−4.7%	[120]
Chemotherapy vs. placebo	36	46%	0.45	70.5%	71%	−0.5%	[121]
Targeted therapy vs. placebo	24	52%	0.20	87.7%	89%	−1.3%	[122]
Targeted therapy vs. placebo	36	80.4%	0.57	88.3%	87.5%	+0.8%	[123]